Diabetic Retinopathy: A Position Statement by the American Diabetes Association

Date: 
March, 2017
March 2017. The American Diabetes Association (ADA) has released a position statement on diabetic retinopathy. This is an update of the ADA’s 2002 position statement. The authors note that, in the past 15 years, “diabetic retinopathy diagnostic assessment and treatment options have improved dramatically.” Clinical advances discussed in this position statement include the role of optical coherence tomography to assess retinal thickness and pathology; wide-field fundus photography to identify silent microvascular lesions; and the role of anti–vascular endothelial growth factor agents in the treatment of diabetic macular edema. The role of medications and devices in overall diabetes therapy and the potential for improved metabolic control in retinopathy prevention are also covered.